Innate Pharma S.A. (OTCMKTS:IPHYF) Short Interest Update

Innate Pharma S.A. (OTCMKTS:IPHYF - Get Free Report) was the target of a significant growth in short interest in May. As of May 15th, there was short interest totalling 21,000 shares, a growth of 6,900.0% from the April 30th total of 300 shares. Based on an average trading volume of 100 shares, the short-interest ratio is currently 210.0 days. Currently, 0.0% of the shares of the stock are short sold.

Innate Pharma Stock Performance

Shares of OTCMKTS IPHYF remained flat at $1.45 during mid-day trading on Monday. The business has a 50-day moving average of $1.72 and a two-hundred day moving average of $2.26. Innate Pharma has a 52-week low of $1.45 and a 52-week high of $1.76.

About Innate Pharma

Innate Pharma SA, a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager.